The global closed system drug transfer device (CSTD) market is expected to grow from US$ 1519.51 million in 2023 to US$ 5206.9 million by 2030, at a CAGR of 22.79%. Closed System Drug Transfer Devices (CSTDs) are medical devices that are used to transfer hazardous drugs from one container to another without exposing healthcare workers to the drug or its aerosolized particles. CSTDs are becoming increasingly popular, as they can help to reduce the risk of occupational exposure to hazardous drugs, which can lead to a number of health problems, including cancer, reproductive problems, and respiratory problems.

The closed system drug-transfer device, or closed system transfer device (CSTD), is a widely used device that stops dangerous environmental toxins from entering the system. Additionally, it limits the amount of dangerous drug vapor concentrations that can exit the system. Currently, there are two basic design approaches used in closed system transfer devices: one that incorporates physical barriers and another that uses air-cleaning technologies. The closed system transfer devices (CSTD) market is anticipated to grow during the forecast period as a result of the growing emphasis on enhancing the general safety of healthcare personnel who are in charge of administering and synthesizing hazardous medications.

Request A Report Sample To Gain Comprehensive Insights! https://bit.ly/3sfUMY9

Closed system drug transfer devices (CSTDs) are medical devices that protect healthcare workers and patients from exposure to hazardous drugs. CSTDs create a closed system during the preparation, administration, and disposal of hazardous drugs, minimizing the risk of drug aerosols, drug contamination, sharps exposure, and hazardous drug exposure.

Key Takeaways:

• The global closed system drug transfer device (CSTD) market is expected to grow from US$ 1519.51 million in 2023 to US$ 5206.9 million by 2030, at a CAGR of 22.79%.
• The growth of the market is attributed to the increasing use of CSTDs to reduce the risk of exposure to hazardous drugs and other hazardous substances, as well as the rising prevalence of cancer and other chronic diseases.
• The oncology segment is expected to account for the largest share of the market during the forecast period, due to the increasing use of CSTDs for the administration of chemotherapy drugs.
• The North American region is expected to dominate the market during the forecast period, owing to the early adoption of CSTDs in the region and the presence of a large number of key players.

Regional Outlook:

• The global CSTD market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
• North America is expected to remain the largest market for CSTDs during the forecast period, owing to the early adoption of CSTDs in the region and the presence of a large number of key players.
• Europe is expected to be the second-largest market for CSTDs during the forecast period, due to the increasing awareness of the benefits of CSTDs and the rising prevalence of chronic diseases in the region.
• The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period, owing to the increasing prevalence of cancer and other chronic diseases, as well as the rising demand for CSTDs in emerging economies such as India and China.

Key Players:

• The key players in the global CSTD market include:
  • BD Medical, Inc.
  • ICU Medical, Inc.
  • Equashield, LLC
  • Hospira
  • Chemolock
  • B. Braun Medical Inc.
  • Teva Medical Ltd.
  • Corvida Medical
  • OnGuard
  • Baxter International Inc.
  • Medline Industries, Inc.

Segmentation:

• The global CSTD market is segmented based on type, application, and end user.

By Type:

• • Closed vial transfer devices
  • Closed syringe transfer devices
  • Closed IV admixtures transfer devices
  • Others

By Application:

• • Oncology
  • Non-oncology

By End User:

• • Hospitals
  • Ambulatory surgical centers
  • Home healthcare
  • Others